NCT03014648View on ClinicalTrials.gov

Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

December 31, 2021

Study Completion Date

March 31, 2022

Conditions
Advanced Non-small Cell Lung Cancer
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.

Trial Locations (2)

15232

UPMC Hillman Cancer Center, Pittsburgh

32804

AdventHealth Orlando, Orlando

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Liza Villaruz, MD

OTHER

NCT03014648 - Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter